SHELTON, Connecticut,
Dec. 2, 2019 /PRNewswire/
-- International medical imaging IT and cybersecurity company
Sectra (STO: SECT B) and Leica Biosystems announce collaboration
for an integrated clinical pathology solution. The goal is to
address the clinical needs of enterprise level customers such as
academic medical centers, clinical research organizations and large
hospital networks. A 510(k) application for the combined solution
has been submitted to the U.S. Food & Drug Administration
(FDA).
"Leveraging Leica Biosystems' existing 510(k) clearance for its
Aperio AT2 DX scanner, and extending it with the Sectra Digital
Pathology Solution for hospitals and health systems, enable us to
deliver a clinical solution to meet the needs of the truly
integrated digital hospitals of today and tomorrow," says Torbjörn
Kronander, Founder & CEO of Sectra. "This is an exciting and
important advancement for the clinical pathology industry and a
huge step forward in clinical usability."
The Sectra digital pathology software solution, a component of
the enterprise imaging offering, will facilitate streamlined image
access, review, and diagnosis, as well as deep integration with
leading pathology information systems and EMRs. Leica Biosystems
Aperio AT2 DX system is a high-throughput automated digital scanner
that delivers diagnostic-quality whole slide images with high
confidence. The integration of these two solid platforms will
enable clinical organizations to deliver a scalable, unified
solution for optimized patient care and financial outcomes.
Leica Biosystems is committed to investing in the development of
Aperio Digital Pathology software, image analysis and hardware
solutions. Moreover, Leica Biosystems recognizes the need for a
wide variety of use cases and applications which simply cannot be
addressed by a single provider. Leica Biosystems' open platform
will enable customers to choose their preferred workflow
solutions.
"This is an important step towards improving patient care with
digital technology," says Colin
White, Global Vice President of Leica Biosystems Advanced
Staining & Imaging Business. "We look forward to working with
Sectra to offer streamlined digital pathology solutions for
clinical organizations."
The clinical use claims described for primary diagnosis have not
been cleared or approved by the U.S. FDA. Any future
capabilities will require FDA clearance before diagnostic
use.
About Sectra Imaging IT Solutions
With more than 25 years of innovation and 1,800 installations,
Sectra is a leading global provider of imaging IT solutions that
support healthcare in achieving patient-centric care. Sectra offers
an enterprise imaging solution comprising PACS for imaging-intense
departments (radiology, pathology, cardiology, orthopedics), VNA,
and share and collaborate solutions. Read more about Sectra and why
Sectra PACS is "Best in KLAS" for a sixth consecutive year at
http://www.sectra.com/medical/.
About Leica Biosystems
Leica Biosystems (LeicaBiosystems.com) is a cancer diagnostics
company and a global leader in workflow solutions, offering the
most comprehensive portfolio from biopsy to diagnosis. With unique
expertise, Leica Biosystems is dedicated to driving innovations
that connect people across radiology, pathology, surgery and
oncology. The mission of "Advancing Cancer Diagnostics, Improving
Lives" is at the heart of the corporate culture. The easy-to-use
and consistently reliable offerings help improve workflow
efficiency and diagnostic confidence. The company is headquartered
in Germany and operates in over
100 countries.
Logo -
https://mma.prnewswire.com/media/962942/Sectra_Logo.jpg
Contact
Andrea Sowitch, Vice President of
Marketing
Sectra, Inc.
E-mail: andrea.sowitch@sectra.com
Phone: 203 925 0899 ext. 268
Torbjörn Kronander, President and CEO
Sectra AB
E-mail: torbjorn.kronander@sectra.se
Phone: +46 705 23 5227
View original content to download
multimedia:http://www.prnewswire.com/news-releases/sectra-and-leica-biosystems-partner-to-pursue-fda-clearance-for-an-integrated-clinical-digital-pathology-solution-300966895.html
SOURCE Sectra, Inc